hematopoietic stem cells

[Molecular Therapy] The authors summarize the status of hematopoietic stem and progenitor cell (HSPC) gene editing, focusing on efficiency, genomic integrity, and long-term engraftment ability related to available genetic editing platforms and HSPC delivery methods.

[Stem Cell Research] Investigators demonstrated that mouse hematopoietic stem cells could be efficiently expanded in polyvinyl alcohol-containing culture medium using only recombinant stem cell factor and thrombopoietin cytokines.

[Blood] To identify genes with the most selective expression in human HSCs, researchers profiled population- and single-cell transcriptomes of un-expanded and ex vivo cultured cord blood-derived hematopoietic stem and progenitor cells as well as peripheral blood, adult bone marrow, and fetal liver.

[International Immunopharmacology] To better understand the role of MSC in the prevention and treatment of graft-versus-host disease, umbilical cord derived MSCs were pre-treated with Chinese medicine Asarinin and IFN-γ.

[Experimental and Molecular Medicine] Scientists investigated the role of microbiota-derived lactate in hematopoiesis using mice deficient in G-protein-coupled receptor (Gpr) 81 (Gpr81−/−), an established lactate receptor. They detected significant depletion of total HSCs in the bone marrow of Gpr81−/− mice compared with heterogenic mice in a steady state.

[Vor Biopharma] Vor Biopharma announced that the US FDA has granted Fast Track designation to VOR33, the company’s lead engineered HSC therapeutic candidate for the treatment of acute myeloid leukemia (AML).